New drug combo targets brain tumor growth
NCT ID NCT05798507
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early trial tests two oral drugs, defactinib and VS-6766, in 14 people with glioblastoma. The goal is to see how much drug reaches the brain tumor and check for side effects. Both drugs block different growth pathways that help glioblastoma cells grow. This study only looks at safety and drug levels, not whether the drugs shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Defactinib and avutometinib (VS-6766)
- What this could lead to
- If successful, this could point toward a new treatment approach for glioblastoma by targeting growth pathways in tumor cells.
- What could go wrong
- This is a very early, small study (14 people) focused on safety and drug levels, not effectiveness. The drugs may not reach enough of the tumor or may cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?
- A simple lotion duo may shield skin from Tumor-Treating fields
- Can a One-Two punch slow recurrent brain cancer?